Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cytyc/Digene

This article was originally published in The Gray Sheet

Executive Summary

Cytyc extends purchase offer expiration date for Digene's outstanding shares to April 11 from March 28 after receiving formal request from FTC for additional information and documentary material concerning the proposed acquisition. Cytyc inked the $554 mil. deal in February (1"The Gray Sheet" Feb. 25, 2002, p. 3)...

You may also be interested in...



Cytyc Gets Digene After Long Courtship, On Verge Of New Indication

The payback on Cytyc's $554 mil. acquisition of Digene could get a quick boost from Digene's pending primary screening indication for DNA Pap for cervical cancer

Moderna Files COVID-19 Vaccine After Second Impressive Read-Out

Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.

Sanofi's Dupixent Cleared For Children With Atopic Dermatitis In EU

The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.

UsernamePublicRestriction

Register

OM006145

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel